Skip to main content
Caplight Logo









Nagi Bioscience SA

Nagi Bioscience SA

Private
Saint-SulpiceHealthcare & Life Scienceshttps://nagibio.ch/

Last Round

Series A

Sep 28, 2023

Total Funding Raised

$18.4M

Company Overview

Nagi Bioscience SA is a biotechnology company that develops and provides organism-on-chip technology for automated biological testing as an alternative to animal testing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

high-throughput screeningmicrofluidicsC. elegansdrug discoverytoxicity testinganimal testing alternativeslab automationhigh-content imagingphenotypic screeningin vitro testingcontract research organizationCROorgan-on-a-chipnew approach methodologiesNAMsrazor-and-blade model

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nagi Bioscience SA Comparables

Compare Nagi Bioscience SA with similar companies based on industry and business-model similarity.

Nagi Bioscience SA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NemaLife
82%
ElegsLab
80%
Magnitude Biosciences
78%

Nagi Bioscience SA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 28, 2023
GrantMar 21, 2022
SeedDec 20, 2019
AcceleratorJan 31, 2019
GrantJul 4, 2018

Key People

Founding team and executive leadership

Matteo Cornaglia

CEO & founder

Founding Team

Nagi Bioscience SA Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2025

    Rhino Bio Inc. will distribute analytical systems in South Korea.

  • Sep 28, 2023

    $14M round led by Swisscanto Private Equity and imec.xpand.

Nagi Bioscience SA Filings

Explore SEC and related filing metadata, where available.

Nagi Bioscience SA filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nagi Bioscience SA's valuation, stock price, and market status.

Is Nagi Bioscience SA a public or private company?

Nagi Bioscience SA is a private company.

What is the current stock price of Nagi Bioscience SA?

Nagi Bioscience SA is a private company with no public stock price. No recent secondary market data is available.

How much is Nagi Bioscience SA worth (valuation)?

Valuation information for Nagi Bioscience SA is not publicly available.

Can I buy Nagi Bioscience SA stock?

Nagi Bioscience SA shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nagi Bioscience SA's last funding round?

Nagi Bioscience SA's most recent funding round was Series A on September 28, 2023.

Who are the main investors in Nagi Bioscience SA?

Key investors in Nagi Bioscience SA include Verve Ventures, imec.xpand.

Will Nagi Bioscience SA IPO soon?

No public IPO plans have been announced for Nagi Bioscience SA.

How can I track Nagi Bioscience SA secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nagi Bioscience SA's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSaint-Sulpice
Employee Range26
Year Founded2019
Last FundingSep 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?